Generic Co. Asks Fed. Circ. To Undo Loss In Takeda IP Fight
By Britain Eakin (June 17, 2022, 6:00 PM EDT) -- Lupin Pharmaceuticals Inc. is urging the Federal Circuit to reverse a decision that its abbreviated new drug application for a proposed generic infringes one of three patents covering Takeda's antidepressant drug Trintellix, saying the district court erred in construing a key claim term.
Lupin said that then-U.S. District Judge Leonard Stark, who was confirmed to the Federal Circuit in March, erred in construing the claim term "reacting," arguing in a brief filed Thursday that its proposed generic does not perform the claimed reacting step under the correct claim construction. The filing came in response to Takeda's appeal of Judge Stark's 2021...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!